Dublin, May 10, 2022 (GLOBE NEWSWIRE) -- The "The Market and Future Potential for Molecular Point of Care (POC), 2022" report has been added to ResearchAndMarkets.com's offering.
The Market and Future Potential for Molecular Point of Care (POC), 2022 provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
This report features a complete update on mPOC and COVID-19. It also discusses other growth areas. Molecular point of care or mPOC systems are designed to be faster than lab-based tests while more accurate than existing point of care systems. Development of new systems and menu expansion on existing lines is constant.
The analyst defines molecular point of care or mPOC as consisting of devices marketed to customers outside the reference lab that run PCR or other DNA and RNA testing on a device with a small footprint. mPOC systems tend to have a result time fast enough for an office visit or bedside consultation. These systems feature cartridges or reduced preparation steps and limited interpretation of test results.
Major IVD companies such as Abbott and Roche and Quidel compete, but there are many other and new entrants since our last reporting.
This was a subset of the testing industry still proving its merit to customers early last year, but certainly the ongoing COVID-19 pandemic has been an influence on the market, as we covered in recent reports. The ability to deliver rapid PCR results has put them in the right place with the right function at the right time.
Many trends are covered in the report, including menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC and other trends.
Key Topics Covered:
Chapter One: Executive Summary
- Molecular Point of Care Market, 2021-2026
- Where is Molecular Point of Care in 2021?
- Molecular Point of Care Market Analysis
- Market Observations
- "Near-Patient" Molecular Systems Market
- Current Trends
- Molecular Point-of-Care Diagnostics Defined
- Usage of Molecular Point of Care
- Leading mPOC Platforms
- Trends
- Scope and Methodology
Chapter Two: Molecular Point-of-Care Market Development and Trends
- COVID-19 and Molecular POC
- CDC Initial Response, Long Term Situation
- COVID-19's Unique Challenge
- BARDA Directs Funding to mPOC
- Recent Regulatory Developments
- Consortia, Funding, Prizes
- Deals
- Advantages and Disadvantages of Molecular Point of Care
- Justification: The Sensitivity/Specificity Argument
- New Systems and Menu Expansion
- Mesa Biotech Strep A Approval
- Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV
- STI Continues to Be a Growth Area
- Deals, Investment in mPOC Systems
- Thermo Acquires Mesa Biotech
- EU Researchers Awarded €3M to Develop POC Molecular Tests
- Scope Fluidics AST System Sees Investment
- China as a POC Market
- Common Tests and Analytes in POC Diagnostics
- Component Technologies of Molecular Point-of-Care Diagnostics
- Microfluidics
- qPCR
- Microarrays
- Isothermal Amplification
- Test Automation
- Primers and Probes
- Detection
- Next-Generation Sequencing
- Molecular Diagnostics
- Real-Time PCR (qPCR)
- Isothermal Amplification Methods
- Line Probe Assays
- Next-Generation Sequencing
- Applications and Potential Applications for Molecular Point-of-Care
- Major Testing Applications for Molecular POC Diagnostics
- Influenza
- Reclassification of RIDTs
- Hospital-Acquired Infections (HAIs)
- Strep A
- Respiratory Syncytial Virus (RSV)
- Emerging Applications
- Zika
- Other Respiratory Infections
- Group B Streptococcus
- Human Papillomavirus
- Herpes Simplex Virus
- Vaginitis
- Malaria
- Other Tropical and Neglected Diseases
- Cancer
- European Device Regulations Nearing
Chapter Three: Market Analysis
- Molecular Point of Care Market Analysis
- "Near Patient Molecular" Market
- Market Share Near Patient
Chapter Four: Company Profiles
- Abbott Laboratories
- Aidian Oy
- Akonni Biosystems
- binx health, inc.
- Biocartis NV
- bioMerieux SA
- Cepheid (Danaher)
- Molecular Healthcare-Acquired Infection (HAI) Testing
- Molecular Sexual Health and Women's Health Testing
- Molecular Critical Infectious Disease Testing
- Molecular Oncology/Genetics Testing
- Credo Diagnostics
- Curetis NV (OpGen)
- DiaSorin S.p.A
- GenMark Diagnostics (Roche)
- Greiner Bio-One GmbH
- Meridian Bioscience, Inc.
- Mesa Biotech, Inc. (Thermo)
- QIAGEN NV
- QuantuMDx Group
- Quidel Corporation
- Roche
- Sekisui Diagnostics LLC
- T2 Biosystems
For more information about this report visit https://www.researchandmarkets.com/r/bm4zrq
